A Phase I/II Clinical Study of Avapritinib in Chinese Subjects With Unresectable or Metastatic Gastrointestinal Stromal Tumor
Latest Information Update: 03 Jan 2024
At a glance
- Drugs Avapritinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors CStone Pharmaceuticals
- 27 Dec 2023 According to a CStone Pharmaceuticals media release, results from a post hoc data analysis of the global Phase 1 NAVIGATOR and Phase 1/2 China bridging (CS3007-101) studies presented at Clinical Cancer Research.
- 27 Dec 2023 Results from a post hoc data analysis of the global Phase 1 NAVIGATOR and Phase 1/2 China bridging (CS3007-101) studies presented in the CStone Pharmaceuticals Media Release
- 27 Dec 2023 Results of post hoc analysis from the global Phase 1 NAVIGATOR study and the Chinese bridging Phase 1/2 CS3007-101 study in patients with advanced gastrointestinal stromal tumors (GIST), presented in the CStone Pharmaceuticals Media Release.